Semaglutide Alleviates Age-Related Dry Eye Disease By Restoring Lacrimal Gland Structure And Function
Dry eye disease, a common and often uncomfortable condition, frequently affects older adults due to changes in the tear-producing glands. Recent research has explored a new potential treatment: a medication called semaglutide. This drug, already known for its benefits in metabolic conditions, appears to offer a promising approach to addressing age-related dry eye.
The study found that semaglutide can significantly improve the symptoms of dry eye and help maintain the health of the lacrimal glands, which are responsible for tear production. It does this by targeting a process called cellular senescence, where cells stop dividing and can contribute to aging and disease. Semaglutide was observed to reduce the number of these “senescent” cells and decrease inflammation in the lacrimal glands.
Furthermore, the medication showed specific positive effects on different types of cells within the glands. It helped alleviate oxidative stress (an imbalance between free radicals and antioxidants) and enhanced stress adaptation in acinar cells (tear-producing cells), suppressed extracellular matrix remodeling (changes in the support structure around cells) and pro-fibrotic programs (processes leading to scarring) in fibroblasts (connective tissue cells), and dampened pro-inflammatory and chemotactic activation (processes that attract immune cells and cause inflammation) in macrophages (immune cells). These combined actions suggest that semaglutide could offer a comprehensive way to combat the underlying causes of age-related dry eye, potentially leading to better and more lasting relief for those affected.
Source: link to paper